Ordering
Available Variants5 mg
CHA.83158-5mg
Price
€115.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.83158-5mg | €115.20 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C25H22N2O2 |
|---|---|
| CAS Number | 174636-32-9 |
| Molecular Weight | 382.45 |
| NACRES | NA.77 |
| PubChem Substance ID | 329825695 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD00944075 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H301 |
| pcodes | P264 - P270 - P301 + P310 - P405 - P501 |
| Hazard Classifications | Acute Tox. 3 Oral |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Talnetant, also known by its CAS number 174636-32-9, is a selective neurokinin 3 receptor antagonist that has been investigated for its potential therapeutic applications. Research has shown that talnetant exhibits high affinity and specificity for the neurokinin 3 receptor, which is involved in various physiological processes, including mood regulation and hormone secretion. As a result, talnetant has been explored as a potential treatment for mood disorders, such as depression and anxiety. Additionally, its mechanism of action suggests that it may also have utility in the treatment of other conditions, including certain endocrine disorders. Further studies are needed to fully elucidate the therapeutic potential of talnetant and to determine its safety and efficacy in human subjects. Ongoing research aims to characterize the pharmacological profile of talnetant and its potential benefits in clinical settings.
